Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Paraneoplastic syndromes in ophthalmology.
J Fr Ophtalmol
May 2018
Ophthalmology Service, CHU de Rennes, 35033 Rennes cedex, France. Electronic address:
Paraneoplastic syndromes involving the visual system are a heterogeneous group of disorders occurring in the setting of systemic malignancy. They are unrelated to local tumor invasion or metastasis and unexplained by nutritional, metabolic, infectious or iatrogenic causes. The presence of antibodies may aid in the diagnosis of a paraneoplastic syndrome, although this is not an absolute requirement.
View Article and Find Full Text PDF3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Muscle Nerve
April 2018
Jacobus Pharmaceutical Company, Princeton, New Jersey.
Introduction: 3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy.
Methods: We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal.
Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment.
J Neurol Sci
January 2014
Department of Neurology, "Alessandro Manzoni" General Hospital, Via Dell'Eremo 9/11, 23900 Lecco, Italy.
Non-paraneoplastic cerebellar ataxia associated with voltage-gated calcium channel (VGCC) antibodies is a rare entity with only few cases reported in literature. We describe a 60 year-old man with subacute cerebellar ataxia and subclinical Lambert-Eaton myasthenic syndrome (LEMS) in whom VGCC antibodies were detected at high titer in serum and cerebrospinal fluid. Screening for underlying malignancies was negative.
View Article and Find Full Text PDF[Eaton-Lambert myasthenic syndrome].
Biomedica
October 2011
Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Primary and secondary small cell neuroendocrine carcinoma of the larynx: a review.
Head Neck
April 2008
Department of Surgical Sciences, ENT Clinic, University of Udine, Udine, Italy.
Primary laryngeal small cell neuroendocrine carcinoma (SCNC) is an unusual malignancy accounting for <0.5% of laryngeal carcinomas. To date, approximately 200 cases of primary and 5 of secondary SCNC of the larynx have been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!